At a glance
ClinicalIndex Comparison RecordN/ACompleted· 81 enrolled
Drug / intervention
Polyoxidoniumdrug
Likely dose
Polyoxidonium 12 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open Observational Study of Efficacy and Safety of Polyoxidonium in Complex Therapy of Hospitalized Patients With COVID-19
In Brief
An observational study evaluating Polyoxidonium for Infections, Coronavirus. Completed, enrolled 81 participants across 5 sites in 2 countries.
Detailed Summary
The study is designed as an open observational non-comparative study of Polyoxidonium®, lyophilizate for solution for injections and topical application, 12 mg in hospitalized patients with coronavirus disease (COVID-19).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsInfections, Coronavirus
CountriesBelarus, Russia
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartMar 2020
Primary CompletionJul 2020
First PostedSep 2020
Study CompletionOct 2020
TodayJul 2026
First PostedSep 9, 2020
Enrollment StartMar 31, 2020
Primary CompletionJul 15, 2020
Study CompletionOct 30, 2020
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 5.8 years ago
Interventions
Polyoxidoniumdrug
Polyoxidonium (azoximer bromide) is administered in the dose of 12 mg (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections)